Ignite Creation Date:
2024-05-05 @ 11:35 AM
Last Modification Date:
2024-10-26 @ 9:10 AM
Study NCT ID:
NCT00088608
Status:
COMPLETED
Last Update Posted:
2016-11-06
First Post:
2004-07-30
Brief Title:
A Study to Assess SOM230 in Patients With Pituitary Cushings Disease
Sponsor:
Novartis Pharmaceuticals
Organization:
Novartis
Study Overview
Official Title:
A Multicenter Open Label Study to Assess the Safety and Efficacy of 600 µg SOM230 Administered Subcutaneously bid in Patients With Cushings Disease
Status:
COMPLETED
Status Verified Date:
2016-11
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The study treatment period is 15 days in length and includes patients with pituitary Cushings disease who are candidates for surgical intervention as well as and patients who have recurrent Cushings post operatively
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None